Dynamic prediction of the risk of recurrence in patients over 60 years of age with differentiated thyroid carcinoma

• Main Authors: Yanina Jimena Morosán, Carina Parisi, María Agustina Urrutia, Melanie Rosmarin, Marta Schnitman, Leonardo Serrano, Wilfrido Luciani, Cristina Faingold, Fabián Pitoia, Gabriela Brenta
• Format: Article
• Language: English
• Published: Brazilian Society of Endocrinology and Metabolism 2016-02-01
• Series: Archives of Endocrinology and Metabolism
• Subjects: Thyroid cancer; elderly; risk re-stratification; recurrence; staging
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000400348&lng=en&tlng=en

ABSTRACT Objective The reclassification of the risk according to the response to the initial treatment makes the treatment of differentiated thyroid cancer (DTC) vary in each individual. As the influence of age on this diagnostic strategy is unknown, we have decided to assess it in adults who are over 60 years of age. Subjects and methods Ninety patients with DTC above 60 years old were enrolled, with total thyroidectomy plus radioiodine ablation, negative anti-thyroglobulin antibodies, follow-up ≥ 2 years and with clinical and pathological information to classify the risk of recurrence according to ATA (American Thyroid Association) and reclassify based on the response to initial therapy according to MSKCC (Memorial Sloan Kettering Cancer Center). The structural persistence at the end of the follow-up was the gold standard of our analysis. Results The structural persistence in ATA low, intermediate and high risk categories was 0, 38, and 100%, respectively. In the intermediate group, none of those with an excellent response to the initial treatment showed structural persistence, whereas 39% of those with an incomplete/indeterminate response showed structural persistence (p < 0.01). Conclusions The re-stratification according to the response to the initial treatment in patients over 60 years of age with an ATA intermediate risk of recurrence allowed for the distinction of disease-free patients at the end of the follow-up from those with structural persistence and a worse clinical progression.